October 2025 – In a significant move that underscores the global advancement of China's pharmaceutical industry, Northeast Pharmaceutical has become the first domestic company to receive a CEP (Certification of Suitability to the European Pharmacopoeia) for the antibiotic ingredient Fosfomycin Trometamol. This milestone grants the company direct access to the stringent European Union market and signals a robust future for Chinese API exporters.
🎯 A Golden Ticket to the EU Market
The CEP, issued by the European Directorate for the Quality of Medicines (EDQM), is widely recognized as a "golden key" to the European and other international markets. This certification demonstrates that Northeast Pharmaceutical's Fosfomycin Trometamol meets the highest international standards for quality, production controls, and purity. For global formulation companies, using a CEP-certified API significantly simplifies and accelerates the process of obtaining marketing authorization in the EU.
🌍 Strategic Position in a Critical Antibiotic Segment
Fosfomycin Trometamol is a valuable antibiotic used for treating respiratory and urinary tract infections. Its low potential for inducing bacterial resistance makes it an increasingly important tool in global healthcare, especially amid the growing challenge of antimicrobial resistance (AMR). This certification allows Northeast Pharmaceutical to supply a high-demand, quality-approved product to one of the world's largest pharmaceutical markets.
🚀 Positive Momentum for Chinese API Exporters
Northeast Pharmaceutical's success is part of a broader, positive trend of Chinese API manufacturers strengthening their global footprint. The company has established an international registration portfolio for about 20 of its core API products, including Vitamin C and Levocarnitine, which are sold in over 100 countries and regions.
Concurrently, other Chinese firms like Guobang Pharmaceutical have also received EU GMP certifications for their antibiotic APIs, further validating the industry's commitment to quality and international compliance.
💡 Future Outlook
This achievement is a powerful example of the strategic shift from simply "exporting products" to building a trusted global brand. With this CEP, Northeast Pharmaceutical is well-positioned to capture a larger share of the premium antibiotic API market, highlighting a promising path forward for Chinese companies in the global high-value pharmaceutical supply chain.